<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 03 Sep 2026 09:00:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Anortech Receives US$1.0 Million Cash and Shares from Sarfartoq Ree Project Transaction</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</link>
   <description>
&lt;p align=&quot;justify&quot;&gt;VANCOUVER, British Columbia, Sept.  03, 2026  (GLOBE NEWSWIRE) -- AnorTech Inc. (“&lt;strong&gt;AnorTech&lt;/strong&gt;” or the “&lt;strong&gt;Company&lt;/strong&gt;”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that, the Company has received cash and shares following the closing of Greenland Mines Ltd.’s acquisition of the Sarfartoq rare earth element (“REE”) project in Greenland from Neo Performance Materials Inc.&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;Under the terms of AnorTech’s agreement with Neo (see NR2026-02), the Company was entitled to receive 5% of the total consideration received in connection with the transfer of the license. Consequently, AnorTech has now received US$1.0 million (C$1.38 million)</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Anortech+Receives+US%241.0+Million+Cash+and+Shares+from+Sarfartoq+Ree+Project+Transaction/27022732.html</guid>
   <pubDate>Thu, 03 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANOR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HUD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines closes Sarfartoq rare earth acquisition in Greenland</title>
   <link>http://www.streetinsider.com/Mergers+and+Acquisitions/Greenland+Mines+closes+Sarfartoq+rare+earth+acquisition+in+Greenland/27016413.html</link>
   <description>

&lt;p&gt;Greenland Mines Ltd (Nasdaq: GRML) completed its acquisition of the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland on September 1, 2026, following approval from the Government of Greenland.&lt;/p&gt;

&lt;p&gt;The company acquired Neo North Star Resources, which holds the Sarfartoq project, in exchange for $20 million in cash and $15 million in securities. Neo Performance Materials Inc. (TSX: NEO) became a strategic shareholder of Greenland Mines through the transaction and retains offtake rights for up to 60% of future Sarfartoq ore or mineral concentrate production for processing at its Silmet rare earth separation facility in Estonia.&lt;/p&gt;

&lt;p&gt;An independent Initial Assessment for the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Mergers+and+Acquisitions/Greenland+Mines+closes+Sarfartoq+rare+earth+acquisition+in+Greenland/27016413.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:22 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines closes Sarfartoq rare earth acquisition in Greenland</title>
   <link>http://www.streetinsider.com/Mergers+and+Acquisitions/Greenland+Mines+closes+Sarfartoq+rare+earth+acquisition+in+Greenland/27016413.html</link>
   <description>

&lt;p&gt;Greenland Mines Ltd (Nasdaq: GRML) completed its acquisition of the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland on September 1, 2026, following approval from the Government of Greenland.&lt;/p&gt;

&lt;p&gt;The company acquired Neo North Star Resources, which holds the Sarfartoq project, in exchange for $20 million in cash and $15 million in securities. Neo Performance Materials Inc. (TSX: NEO) became a strategic shareholder of Greenland Mines through the transaction and retains offtake rights for up to 60% of future Sarfartoq ore or mineral concentrate production for processing at its Silmet rare earth separation facility in Estonia.&lt;/p&gt;

&lt;p&gt;An independent Initial Assessment for the</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Mergers+and+Acquisitions/Greenland+Mines+closes+Sarfartoq+rare+earth+acquisition+in+Greenland/27016413.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:22 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval</title>
   <link>http://www.streetinsider.com/Press+Releases/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</link>
   <description>&lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;At 2025 consumption levels, the NdPr oxide Sarfartoq is expected to produce annually from ST1 alone would represent approximately 34% of all NdPr oxide refined outside China&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;Transaction closed September 1 following Government of Greenland approval&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;left&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;CHARLOTTE, N.C., Sept.  02, 2026  (GLOBE NEWSWIRE) -- &lt;/i&gt;via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML), a Western-aligned critical minerals developer consummated the closing of the Sarfartoq Nd-Pr Rare Earths Project in southwest Greenland, on Tuesday, September 1, 2026. The closing completes the transaction contemplated by the definitive acquisition</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval</title>
   <link>http://www.streetinsider.com/Press+Releases/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</link>
   <description>&lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;At 2025 consumption levels, the NdPr oxide Sarfartoq is expected to produce annually from ST1 alone would represent approximately 34% of all NdPr oxide refined outside China&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;Transaction closed September 1 following Government of Greenland approval&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;left&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;CHARLOTTE, N.C., Sept.  02, 2026  (GLOBE NEWSWIRE) -- &lt;/i&gt;via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML), a Western-aligned critical minerals developer consummated the closing of the Sarfartoq Nd-Pr Rare Earths Project in southwest Greenland, on Tuesday, September 1, 2026. The closing completes the transaction contemplated by the definitive acquisition</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</link>
   <description>&lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;At 2025 consumption levels, the NdPr oxide Sarfartoq is expected to produce annually from ST1 alone would represent approximately 34% of all NdPr oxide refined outside China&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;Transaction closed September 1 following Government of Greenland approval&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;left&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;CHARLOTTE, N.C., Sept.  02, 2026  (GLOBE NEWSWIRE) -- &lt;/i&gt;via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML), a Western-aligned critical minerals developer consummated the closing of the Sarfartoq Nd-Pr Rare Earths Project in southwest Greenland, on Tuesday, September 1, 2026. The closing completes the transaction contemplated by the definitive acquisition</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</link>
   <description>&lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;At 2025 consumption levels, the NdPr oxide Sarfartoq is expected to produce annually from ST1 alone would represent approximately 34% of all NdPr oxide refined outside China&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;Transaction closed September 1 following Government of Greenland approval&lt;/i&gt;&lt;/p&gt;  &lt;p align=&quot;left&quot; style=&quot;padding-left:0in;&quot;&gt;&lt;i&gt;CHARLOTTE, N.C., Sept.  02, 2026  (GLOBE NEWSWIRE) -- &lt;/i&gt;via IBN – Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML), a Western-aligned critical minerals developer consummated the closing of the Sarfartoq Nd-Pr Rare Earths Project in southwest Greenland, on Tuesday, September 1, 2026. The closing completes the transaction contemplated by the definitive acquisition</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Greenland+Mines+Completes+Acquisition+of+World-Class+Rare+Earth+Nd-Pr+Magnet+and+Defense+Mine+Asset+Following+Greenland+Government+Approval/27016339.html</guid>
   <pubDate>Wed, 02 Sep 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GRML</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>NeoGenomics wins Medicare coverage for cancer immunotherapy test</title>
   <link>http://www.streetinsider.com/Corporate+News/NeoGenomics+wins+Medicare+coverage+for+cancer+immunotherapy+test/26982035.html</link>
   <description>&lt;p&gt;NeoGenomics, Inc. (NASDAQ: NEO) announced that its RaDaR ST molecular residual disease (MRD) assay has received expanded Medicare coverage from the Centers for Medicare &amp; Medicaid Services' Molecular Diagnostic Services Program to include immunotherapy response monitoring in patients with late-stage solid tumors.&lt;/p&gt;&lt;p&gt;This marks the third Medicare-covered indication for RaDaR ST. The test was previously covered for HPV-negative head and neck squamous cell carcinoma and a subset of hormone receptor-positive, HER2-negative breast cancer. NeoGenomics said it has two additional RaDaR ST submissions pending with the program.&lt;/p&gt;&lt;p&gt;The new coverage applies to monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Corporate+News/NeoGenomics+wins+Medicare+coverage+for+cancer+immunotherapy+test/26982035.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:33 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring</title>
   <link>http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    FORT MYERS, Fla.--(BUSINESS WIRE)--
&lt;b&gt;NeoGenomics, Inc. (NASDAQ: NEO)&lt;/b&gt;, a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare &amp;amp; Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

&lt;/p&gt;&lt;p&gt;
Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/NeoGenomics+Receives+Medicare+Coverage+for+RaDaR+ST+for+Immunotherapy+Treatment+Response+Monitoring/26981995.html</guid>
   <pubDate>Wed, 26 Aug 2026 16:17:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.28005717</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20020231</category>
   	  </item>
  <item>
   <title>Form  4          NEOGENOMICS INC           For: Aug 21  Filed by: Stone Warren</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html</link>
   <description>si-local-file:///var/storage/secattach/20260825/26975213.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html</guid>
   <pubDate>Tue, 25 Aug 2026 16:33:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	  </item>
  <item>
   <title>Form  4          NEOGENOMICS INC           For: Aug 21  Filed by: Stone Warren</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html</link>
   <description>si-local-file:///var/storage/secattach/20260825/26975213.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NEOGENOMICS+INC+++++++++++For%3A+Aug+21++Filed+by%3A+Stone+Warren/26975213.html</guid>
   <pubDate>Tue, 25 Aug 2026 16:33:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	  </item>
  <item>
   <title>Form  S-8        NEOGENOMICS INC                      </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html</link>
   <description>si-local-file:///var/storage/secattach/20260825/26974593.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html</guid>
   <pubDate>Tue, 25 Aug 2026 16:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	  </item>
  <item>
   <title>Form  S-8        NEOGENOMICS INC                      </title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html</link>
   <description>si-local-file:///var/storage/secattach/20260825/26974593.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NEOGENOMICS+INC++++++++++++++++++++++/26974593.html</guid>
   <pubDate>Tue, 25 Aug 2026 16:02:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NEO</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01687242</category>
   	  </item>
 </channel>
</rss>
